418
M. Gonza´lez et al. / Il Farmaco 58 (2003) 409Á418
/
[9] J.M. Gwaltney, S. Savolainen, P. Rivas, Comparative effective-
ness and safety of cefdinir and amoxicillinÁclavulanate in
treatment of acute community-acquired bacterial sinusitis, Anti-
microb. Agents Chemother. 41 (1997) 1517Á1520.
4. Conclusions
/
Cefdinir was prepared by an alternative synthetic
route which allowed to avoid the use of diketene and to
obtain better yields than in the previously reported
method.
/
[10] K.J. Tack, T.W. Littlejohn, G.W. Mailloux, M. Michelle, C.H.
Keyserling, Cefdinir versus cephalexin for treatment of skin and
skin-structure infections, Clin. Ther. 20 (1998) 244Á256.
/
[11] M.A. Cohen, G.E. Roland, M.D. Huband, Cefdinir (CI-983), a
new oral cephalosporin: in vitro evaluation against respiratory
and urogenital tract pathogen species [abst 1532], in: Program and
Abstracts of the 31st Interscience Conference on Antimicrobial
Agents and Chemotherapy, Chicago, IL, American Society for
Microbiology, Washington, DC, 1991, p. 354.
In the course of the present research, two procedures
were developed to protect the cephem amino function by
phenylacetylation during the synthesis of compound II.
In both cases, yields were higher than those described in
the previously reported method. It was demonstrated
that the use (as acylating agent) of phenylacetic acid
activated by Vilsmeier reagent allowed to obtain the best
yields of II.
[12] T. Nishimura, K. Tabuki, S. Aoki, M. Takagi, Laboratory and
clinical studies of cefdinir 5 and 10% fine granules in pediatric
field, Jpn. J. Antibiot. 44 (1991) 1142Á1157.
/
[13] F. Kees, H. Grobecker, Systematics of beta-lactams: chemical
On the other hand, two methods were developed in
order to form the 2-aminothiazol ring during the
synthesis of compound VII. It was demonstrated that
the use of N,N-dimethylacetamide as a solvent was the
best choice and allowed to obtain better yields of VII
than those described in the previously reported methods.
Finally, it was developed a method to acylate compound
IV directly with the sodium salt IX. This procedure
allowed to overcome the drawback corresponding to the
conversion of IX into its free acid form.
properties and structure activity relationship of oral cephalospor-
ins, Antibiot. Chemother. 47 (1995) 7Á9.
/
[14] Y. Inamoto, T. Chiba, T. Kamimura, T. Takaya, FK 482, a new
orally active cephalosporin. Synthesis and biological properties, J.
Antibiot. 41 (1988) 828Á830.
/
[15] T. Takaya, H. Takasugi, T. Masugi, H. Yamanaka, K. Kawa-
bata, 7-Substituted-3-vinyl-3-cephem compounds and processes
for production of the same, US Pat. 4 559 334, Chem. Abstr.
(1981) 95: P150687e.
[16] R. Heymes, A. Lutz, 3-Acetoxymethyl-7-(iminoacetamido)-ce-
phalosporanic acid derivatives, US Pat. 4 152 432, Chem. Abstr.
(1977) 87: P168063t.
[17] H. Kamachi, Y. Narita, T. Okita, Y. Abe, S. Imura, K. Tomatsu,
T. Yamasaki, J. Okumura, T. Naito, T. Oki, H. Kawaguchi,
Synthesis and biological activity of a new cephalosporin, BMY-
28232 and its prodrug-type esters for oral use, J. Antibiot. 41
References
(1988) 1602Á1616.
/
[1] H.C. Neu, G. Saha, N.-X. Chin, Comparative in vitro activity and
[18] T. Takaya, H. Takasugi, T. Murakawa, H. Nakano, Studies on b-
lactam antibiotics. III. Synthesis and enzymatic stability of 3-
acyloxymethyl-7(-[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxymi-
no)acetamido]-3-cephem-4-carboxylic acids, J. Antibiot. 34 (1981)
b-lactamase stability of FK482,
Antimicrob. Agents Chemother. 33 (1989) 17955Á
[2] M.A. Cohen, E.T. Joannides, G.E. Roland, In vitro evaluation of
cefdinir (FK482), new oral cephalosporin with enhanced
antistaphylococcal activity and b-lactamase stability, Diagn.
Microbiol. Infect. Dis. 18 (1994) 31Á39.
[3] M.A. Cohen, S.A. Wold, M.A. Merservey, In vivo therapeutic
efficacy of cefdinir (FK482), a new oral cephalosporin, against
Staphylococcus aureus and Haemophilus influenzae in mouse
a
new oral cephalosporin,
/18000.
a
1300Á1318.
/
[19] H. Yamanaka, T. Chiba, K. Kawabata, H. Takasugi, T. Masugi,
T. Takaya, Studies on b-lactam antibiotics IX. Synthesis and
biological activity of a new orally active cephalosporin, cefixime
/
(FK 027), J. Antibiot. 38 (1985) 1738Á1751.
/
[20] R.R. Chauvette, H.B. Hayes, G.L. Huff, P.A. Pennington,
infection models, Diagn. Microbiol. Infect. Dis. 18 (1994) 41Á47.
/
Preparation of 7-aminocephalosporanic acid and 6-aminopenicil-
[4] T. Sultan, A. Baltch, R.P. Smith, W. Ritz, In vitro activity of
cefdinir (FK 482) and ten other antibiotics against gram-positive
and gram-negative isolated from adult and pediatric patients,
lanic acid, J. Antibiot. 25 (1972) 248Á250.
/
[21] W.H.W. Lunn, R.W. Burchfield, T.K. Elzey, E.V. Mason,
Cleavage of 7a-methoxycephalosporin C derivatives with phos-
porous pentachloride, Tetraedron Lett. 14 (1974) 1307Á1310.
Chemotherapy (Switzerland) 40 (1994) 80Á91.
/
/
[5] M.J. Sperling, A. Puopolo, T.J. Griffin, C.H. Keyserling, K.J.
Tack, Efficacy and safety of cefdinir in the treatment of patients
with acute bronchitis. The Cefdinir Bronchitis Study Groups,
[22] R. Bucourt, R. Heymes, A. Lutz, L. Pe´nasse, J. Perronet,
Cephalosporines a chaines amino-2-thiazolyl-4-acetyles, Tetrae-
dron 34 (1978) 2233Á2243.
/
Clin. Ther. 18 (1996) 626Á634.
/
[23] Glaxo Group Ltd., Nouvelles ce´phalosporines, leur proce´de´ de
pre´paration et leur application the´rapeutique, Fr. Pat. 2 426 695,
Chem. Abstr. (1980) 92: 198413c.
[6] S.R. Scriver, B.M. Willey, D.E. Low, Comparative in vitro
activity of cefdinir (CI-983; FK482) against stapylococcus, gram
negatives bacilli and respiratory tract pathogens, Eur. J. Clin.
[24] R. Latrell, J. Blumbach, W. Duerckheimer, H.W. Fehlhaber, K.
Fleischmann, R. Kirrstetter, B. Mencke, K.H. Scheunemann, E.
Schrinner, W. Schwab, K. Seeger, G. Seibert, M. Wieduwitt,
Synthesis and structure-activity relationships in the cefpirome
series. I. 7-[2-(2-aminothiazol-4-yl)-2-(Z) oxyminoacetamido]-3-
[(substituted-1-pyridinio)methyl]-ceph-em-4-carboxylates, J. Anti-
Microbiol. Infect. Dis. 11 (1992) 646Á652.
[7] M. Dreholb, P. Bianchi, C.H. Keyserling, Comparison of cefdinir
and cefaclor in treatment of community acquired pneumonia,
/
Antimicrob. Agents Chemother. 41 (1997) 1579Á1583.
[8] J.T. Kenneth, D.C. Henry, W.M. Gooch, D.N. Brink, C.H.
Keyserling, Five-day cefdinir treatment for streptococcal phar-
/
yngitis, Antimicrob. Agents Chemother. 42 (1998) 1073Á
/1075.
biot. 41 (1988) 1374Á1394.
/